Point-of-Care Glucose Testing Market growth is driven by Rising Awareness about Diabetes Management

Point-of-Care Glucose Testing Industry Overview

The global point-of-care glucose testing market size was valued at USD 3.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030. The growing geriatric population, the ability of point-of-care (POC) diagnostic tests to deliver immediate results, thus providing improved patient care, and rising market penetration of Electronic Medical Records (EMRs) are among the high-impact rendering drivers of this market. The shortage of skilled staff, especially in the field of diagnostics, is also expected to increase the market penetration of glucose POC diagnostic products. The market is expected to gain momentum as the presence of diabetes increases the risk of mortality from COVID-19.

Thus, diabetes management is one of the key priorities among healthcare professionals to limit the mortality rate. According to a survey by the Diabetes Research Foundation, diabetes increases the risk of a fatal outcome by 50% among COVID-19 patients. The growing awareness about diabetes management, poor healthcare access, scarcity of healthcare professionals, and the highest global prevalence recorded in Asian countries are likely to increase the adoption of PoC glucose testing solutions. This, in turn, creates an opportunity to reduce the healthcare burden by improving patient outcomes.

Gather more insights about the market drivers, restraints, and growth of the Global Point-of-Care Glucose Testing Market

The introduction of favorable regulatory policies aimed at promoting PoC glucose diagnostics is expected to serve as a high-impact rendering driver for the market. For example, in the U.S., the implementation of Clinical Laboratory Improvement Amendments (CLIA) is expected to boost usage rates during the forecast period. CLIA-waived tests are approved for use by healthcare providers operating in nontraditional laboratory sites, such as emergency rooms, physician offices, pharmacy clinics, health department clinics, and other healthcare facilities. The prevalence of diabetes is increasing worldwide, which is expanding the patient pool for the market.

Furthermore, the presence of unmet medical needs for diagnosis and management of diabetes and the increase in patient awareness are expected to boost the demand for POC diagnostics. According to the International Diabetes Federation, an estimated 537 million people had diabetes in 2021, and the number is projected to increase to 643 million by 2030 and 783 million by 2045. The healthcare industry is focusing on shorter hospital stays, better acute care, and the expansion of outlying surgical centers, which has consequently increased the demand for Short Turn-Around Testing (STAT). POC management solutions allow patients and healthcare providers to easily collect, share, and manage specimens to meet regulatory requirements.

Browse through Grand View Research's Medical Devices Industry Related Reports

Glucose Biosensors Market - The global glucose biosensors market size was valued at USD 10,206.3 million in 2021 and is anticipated to expand at a CAGR of 7.9% during the forecast period.

Blood Glucose Monitoring Devices Market - The global blood glucose monitoring devices market size was valued at 11.71 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2022 to 2030.

Point-of-Care Glucose Testing Industry Segmentation

Grand View Research has segmented the global point-of-care glucose testing market based on product, end use and region:

PoC Glucose Testing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Accu Check Aviva Meter
• Onetouch Verio Flex
• i-STAT
• Freestyle Lite
• Bayer CONTOUR Blood Glucose Monitoring System
• True Metrix
• Accu-Chek Inform II
• StatStrip
• Others

PoC Glucose Testing End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital
• Home setting
• Diagnostic center

Point-of-Care Glucose Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• Europe
• Asia Pacific
• Latin America
• MEA (Middle East & Africa)

Market Share Insights:

June 2020: Tandem Diabetes Care and Abbott finalized an agreement to commercialize and develop an integrated diabetes solution that combines Tandem’s insulin delivery system and Abbott’s CGM technology.

Key Companies profiled:

Some prominent players in the global Point-of-Care Glucose Testing Industry include

• F. Hoffmann-La Roche Ltd.
• Abbott
• Nipro
• PlatInium Equity Advisors, LLC (Lifescan, Inc.)
• Nova Biomedical
• ACON Laboratories
• Trividia Health, Inc.
• Prodigy Diabetes Care, LLC
• Bayer AG/Ascensia Diabetes Care Holdings AG
• EKF Diagnostics

Order a free sample PDF of the Point-of-Care Glucose Testing Market Intelligence Study, published by Grand View Research.